Epsilogen Ltd Employee Directory
Biotechnology ResearchEngland, United Kingdom11-50 Employees
Epsilogen Ltd is a London-based biotechnology company focused on developing immunoglobulin E antibodies for cancer therapy. IgE antibodies are explored for potential advantages in solid tumors, including increased potency, better tumor access, and a longer tissue residence time. Its lead program targets the folate receptor alpha (FR alpha) with an anti-FR alpha IgE antibody currently in a phase I trial for ovarian cancer, noted as the first IgE therapeutic to reach the clinic. Operating in biotechnology research, the firm maintains a relatively small workforce. In 2025, Epsilogen completed the acquisition of TigaTx, Inc., strengthening its portfolio with engineered IgA antibodies to pursue a pan-isotype approach to cancer therapy. The same year saw leadership updates with the appointment of Cristina Oliva as Chief Medical Officer, reflecting continued clinical oversight and governance.
1-888-653-2347 
support@leadiq.com 
